Equities Analysts Set Expectations for ANRO Q1 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities research analysts at HC Wainwright issued their Q1 2027 EPS estimates for Alto Neuroscience in a report issued on Thursday, April 2nd. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.78) per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q2 2027 earnings at ($0.85) EPS, Q3 2027 earnings at ($0.91) EPS and Q4 2027 earnings at ($0.90) EPS.

A number of other equities research analysts have also recently commented on ANRO. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Wedbush decreased their target price on shares of Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a research report on Thursday, April 2nd. JonesTrading decreased their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. BTIG Research upped their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Finally, Chardan Capital reiterated a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a research note on Thursday, April 2nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Alto Neuroscience Trading Down 5.7%

NYSE:ANRO opened at $21.24 on Tuesday. Alto Neuroscience has a 52 week low of $1.90 and a 52 week high of $25.17. The firm has a 50 day moving average of $19.49 and a 200 day moving average of $15.21. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $678.46 million, a price-to-earnings ratio of -9.74 and a beta of 2.01.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Monday, March 16th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11.

Institutional Investors Weigh In On Alto Neuroscience

Large investors have recently bought and sold shares of the company. XTX Topco Ltd increased its holdings in Alto Neuroscience by 32.2% in the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after buying an additional 5,078 shares during the period. Ikarian Capital LLC lifted its stake in Alto Neuroscience by 368.2% during the 4th quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock valued at $9,167,000 after acquiring an additional 405,000 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after acquiring an additional 1,535,000 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Alto Neuroscience in the fourth quarter worth $1,228,000. Finally, Perceptive Advisors LLC increased its stake in shares of Alto Neuroscience by 1,048.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after acquiring an additional 1,629,027 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.